Reckitt stock jumps on baby formula legal victory, JPMorgan upgrade
Reckitt shares rose 4% after a U.S. jury ruled in favor of its Mead Johnson unit in a baby formula lawsuit. JPMorgan upgraded Reckitt to Overweight, raising its 2027 price target to 6,500 pence. Analysts cited positive catalysts and improved litigation outlook for Mead Johnson, along with strong core sales growth.
How this was made
The 30-second read
Why it matters
The legal win removes a major uncertainty, supporting a price rally and justifying the JPMorgan upgrade.
Market read
The combination of a favorable court decision and an analyst upgrade drives a notable short-term price move.
What to watch
Potential settlement costs or future regulatory scrutiny of baby formula products.
Background
Reckitt Benckiser (RKT) faced ongoing NEC litigation over its Enfamil preterm formula. The recent jury verdict is the first bellwether case.
Ticker impact
Reckitt shares jumped >4% after a U.S. jury ruled in favor of its Mead Johnson unit and JPMorgan upgraded the stock to Overweight.
Expect continued upside pressure, potential 5-7% rally in the short term.
The verdict eliminates a major risk factor and the analyst upgrade adds fresh buy-side pressure.
Market effects
Other consumer staples may see reduced litigation risk perception.
European consumer staples gain confidence from the verdict.
Highlights the impact of litigation outcomes on multinational consumer goods firms.
Counterpoint
The verdict may be an outlier; future litigation could still pose risks.
Key entities
- CompanyReckitt Benckiser
Consumer goods group with Mead Johnson baby formula business.
- AnalystJPMorgan
Upgraded Reckitt to Overweight with a higher price target.


